[Treatment of diaper rash with Parfenac lipid ointment (bufexamac). A study by Austrian pediatricians]

Area of Science:

• Dermatology
• Pediatrics
• Pharmacology

Background:

• Diaper dermatitis is a common inflammatory skin condition in infants.
• Topical treatments are essential for managing diaper dermatitis.
• Minimizing corticosteroid use in infants is a clinical goal.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Parfenac-Fettsalbe (Bufexamac) for treating diaper dermatitis in children aged 0-24 months.
• To assess treatment outcomes in relation to patient demographics.
• To explore potential reasons for non-response to treatment.

Main Methods:

• A cohort of 447 infants (0-24 months) with diaper dermatitis received topical Parfenac-Fettsalbe.
• Patient outcomes were categorized as 'very good' (no efflorescences) or 'good' (some efflorescences).
• Local side effects and response rates were recorded.

Main Results:

• Over 80% of treated children achieved very good or good results.
• Higher efficacy was observed in girls (62.71% very good) compared to boys (59.89% very good).
• The medication was well-tolerated, with only 7 children experiencing local side effects.

Conclusions:

• Parfenac-Fettsalbe (Bufexamac) is an effective and well-tolerated antiphlogistic treatment for diaper dermatitis in infants.
• It provides a viable alternative to corticosteroid avoidance.
• Superinfection with microorganisms like Candida and Staphylococci may contribute to treatment non-response.